Pemetrexed for the treatment of non-small cell lung cancer

Carlo Genova, Erika Rijavec, Anna Truini, Simona Coco, Claudio Sini, Giulia Barletta, Maria Giovanna Dal Bello, Angela Alama, Grazia Savarino, Paolo Pronzato, Francesco Boccardo, Francesco Grossi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed, a multi-target folate antagonist, has improved the survival of non-squamous NSCLC patients. Currently, pemetrexed is approved for first-line treatment in combination with a platinum derivate, for second-line treatment as a single agent and, more recently, as maintenance treatment after first-line chemotherapy. Areas covered: The authors analyzed the state of the art of pemetrexed through a review of the literature. Clinical trials and meta-analyses involving pemetrexed in NSCLC were evaluated. Pemetrexed improved survival of non-squamous NSCLC in first-line, maintenance, and second-line treatments; this benefit is limited to non-squamous histology. Because pemetrexed has become part of the standard of care, current clinical trials are designed to compare it to other investigational combinations. Limited data on resectable disease are available, and additional clinical trials are being conducted. Expert opinion: Pemetrexed has shown effectiveness and a favorable toxicity profile. Histology-driven indications and the relationship of pemetrexed with thymidylate synthase expression suggest that a more precise definition of predictive biomarkers could be further investigated.

Original languageEnglish
Pages (from-to)1545-1558
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number11
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Pemetrexed
Non-Small Cell Lung Carcinoma
Clinical Trials
Therapeutics
Histology
Thymidylate Synthase
Survival
Expert Testimony
Standard of Care
Platinum
Folic Acid
Meta-Analysis
Biomarkers
Maintenance

Keywords

  • Chemotherapy
  • Non-small cell lung cancer
  • Pemetrexed
  • Thymidylate synthase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Genova, C., Rijavec, E., Truini, A., Coco, S., Sini, C., Barletta, G., ... Grossi, F. (2013). Pemetrexed for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 14(11), 1545-1558. https://doi.org/10.1517/14656566.2013.802774

Pemetrexed for the treatment of non-small cell lung cancer. / Genova, Carlo; Rijavec, Erika; Truini, Anna; Coco, Simona; Sini, Claudio; Barletta, Giulia; Dal Bello, Maria Giovanna; Alama, Angela; Savarino, Grazia; Pronzato, Paolo; Boccardo, Francesco; Grossi, Francesco.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 11, 08.2013, p. 1545-1558.

Research output: Contribution to journalArticle

Genova, C, Rijavec, E, Truini, A, Coco, S, Sini, C, Barletta, G, Dal Bello, MG, Alama, A, Savarino, G, Pronzato, P, Boccardo, F & Grossi, F 2013, 'Pemetrexed for the treatment of non-small cell lung cancer', Expert Opinion on Pharmacotherapy, vol. 14, no. 11, pp. 1545-1558. https://doi.org/10.1517/14656566.2013.802774
Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G et al. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy. 2013 Aug;14(11):1545-1558. https://doi.org/10.1517/14656566.2013.802774
Genova, Carlo ; Rijavec, Erika ; Truini, Anna ; Coco, Simona ; Sini, Claudio ; Barletta, Giulia ; Dal Bello, Maria Giovanna ; Alama, Angela ; Savarino, Grazia ; Pronzato, Paolo ; Boccardo, Francesco ; Grossi, Francesco. / Pemetrexed for the treatment of non-small cell lung cancer. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 11. pp. 1545-1558.
@article{760989696e4a45fba836338f916eae4d,
title = "Pemetrexed for the treatment of non-small cell lung cancer",
abstract = "Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed, a multi-target folate antagonist, has improved the survival of non-squamous NSCLC patients. Currently, pemetrexed is approved for first-line treatment in combination with a platinum derivate, for second-line treatment as a single agent and, more recently, as maintenance treatment after first-line chemotherapy. Areas covered: The authors analyzed the state of the art of pemetrexed through a review of the literature. Clinical trials and meta-analyses involving pemetrexed in NSCLC were evaluated. Pemetrexed improved survival of non-squamous NSCLC in first-line, maintenance, and second-line treatments; this benefit is limited to non-squamous histology. Because pemetrexed has become part of the standard of care, current clinical trials are designed to compare it to other investigational combinations. Limited data on resectable disease are available, and additional clinical trials are being conducted. Expert opinion: Pemetrexed has shown effectiveness and a favorable toxicity profile. Histology-driven indications and the relationship of pemetrexed with thymidylate synthase expression suggest that a more precise definition of predictive biomarkers could be further investigated.",
keywords = "Chemotherapy, Non-small cell lung cancer, Pemetrexed, Thymidylate synthase",
author = "Carlo Genova and Erika Rijavec and Anna Truini and Simona Coco and Claudio Sini and Giulia Barletta and {Dal Bello}, {Maria Giovanna} and Angela Alama and Grazia Savarino and Paolo Pronzato and Francesco Boccardo and Francesco Grossi",
year = "2013",
month = "8",
doi = "10.1517/14656566.2013.802774",
language = "English",
volume = "14",
pages = "1545--1558",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Pemetrexed for the treatment of non-small cell lung cancer

AU - Genova, Carlo

AU - Rijavec, Erika

AU - Truini, Anna

AU - Coco, Simona

AU - Sini, Claudio

AU - Barletta, Giulia

AU - Dal Bello, Maria Giovanna

AU - Alama, Angela

AU - Savarino, Grazia

AU - Pronzato, Paolo

AU - Boccardo, Francesco

AU - Grossi, Francesco

PY - 2013/8

Y1 - 2013/8

N2 - Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed, a multi-target folate antagonist, has improved the survival of non-squamous NSCLC patients. Currently, pemetrexed is approved for first-line treatment in combination with a platinum derivate, for second-line treatment as a single agent and, more recently, as maintenance treatment after first-line chemotherapy. Areas covered: The authors analyzed the state of the art of pemetrexed through a review of the literature. Clinical trials and meta-analyses involving pemetrexed in NSCLC were evaluated. Pemetrexed improved survival of non-squamous NSCLC in first-line, maintenance, and second-line treatments; this benefit is limited to non-squamous histology. Because pemetrexed has become part of the standard of care, current clinical trials are designed to compare it to other investigational combinations. Limited data on resectable disease are available, and additional clinical trials are being conducted. Expert opinion: Pemetrexed has shown effectiveness and a favorable toxicity profile. Histology-driven indications and the relationship of pemetrexed with thymidylate synthase expression suggest that a more precise definition of predictive biomarkers could be further investigated.

AB - Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed, a multi-target folate antagonist, has improved the survival of non-squamous NSCLC patients. Currently, pemetrexed is approved for first-line treatment in combination with a platinum derivate, for second-line treatment as a single agent and, more recently, as maintenance treatment after first-line chemotherapy. Areas covered: The authors analyzed the state of the art of pemetrexed through a review of the literature. Clinical trials and meta-analyses involving pemetrexed in NSCLC were evaluated. Pemetrexed improved survival of non-squamous NSCLC in first-line, maintenance, and second-line treatments; this benefit is limited to non-squamous histology. Because pemetrexed has become part of the standard of care, current clinical trials are designed to compare it to other investigational combinations. Limited data on resectable disease are available, and additional clinical trials are being conducted. Expert opinion: Pemetrexed has shown effectiveness and a favorable toxicity profile. Histology-driven indications and the relationship of pemetrexed with thymidylate synthase expression suggest that a more precise definition of predictive biomarkers could be further investigated.

KW - Chemotherapy

KW - Non-small cell lung cancer

KW - Pemetrexed

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=84880122419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880122419&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.802774

DO - 10.1517/14656566.2013.802774

M3 - Article

C2 - 23683110

AN - SCOPUS:84880122419

VL - 14

SP - 1545

EP - 1558

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 11

ER -